دورية أكاديمية
أعرض في EDS

Characteristics of appendicitis after immune checkpoint inhibitor therapy among cancer patients.

التفاصيل البيبلوغرافية
العنوان: Characteristics of appendicitis after immune checkpoint inhibitor therapy among cancer patients.
المؤلفون: Mathew A; Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA., Shatila M; Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lai Z; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tan D; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Oliva ICG; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang J; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Alhalabi O; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhang HC; Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Thomas A; Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang Y; Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ywang59@mdanderson.org.
المصدر: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2023 Jul; Vol. 149 (8), pp. 4591-4599. Date of Electronic Publication: 2022 Sep 26.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7902060 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1335 (Electronic) Linking ISSN: 01715216 NLM ISO Abbreviation: J Cancer Res Clin Oncol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Berlin ; New York : Springer-Verlag.
مواضيع طبية MeSH: Appendicitis*/surgery , Appendicitis*/chemically induced , Appendicitis*/drug therapy , Antineoplastic Agents, Immunological*/therapeutic use , Neoplasms*/drug therapy, Adult ; Humans ; Middle Aged ; Immune Checkpoint Inhibitors/adverse effects ; Retrospective Studies
مستخلص: Purpose: Immune checkpoint inhibitor (ICI) therapy has revolutionized cancer care but is associated with immune-related adverse events (irAEs). Recent case reports raised the concern that acute appendicitis may be an irAE. In this study, we sought to describe the disease course of post-ICI therapy appendicitis and its associated complications.
Methods: Adult patients who had an International Classification of Diseases code for appendicitis within the first 2 years after initiating ICI therapy from January 2010 to April 2021 and who had imaging evidence of appendicitis were studied retrospectively.
Results: 13,991 patients were identified who had ICI exposure during the study period, 44 had codes for appendicitis, 10 of whom met the inclusion criteria. Their median age at the time of diagnosis was 59 years. The median time from ICI therapy initiation to appendicitis onset was 188 days. The most common presenting symptoms were abdominal pain (70%) and fever (40%). Abscesses were present in two patients, and a perforation was present in one. All 10 patients received broad-spectrum antibiotics. Five patients needed surgery or interventional radiology drainage. Nine patients had resolution of appendicitis symptoms after treatment.
Conclusion: Post-ICI therapy appendicitis is rare but presents similarly to and has similar complications rates as conventional appendicitis. Appendectomy remains the mainstay of treatment, but its use can be limited in cancer patients. The decision to continue ICI therapy remains at the discretion of the clinician. Further studies are needed to bring awareness to and advance the understanding of this clinical entity.
(© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
References: Abu-Sbeih H, Wang Y (2020) Management considerations for immune checkpoint inhibitor-induced enterocolitis based on management of inflammatory bowel disease. Inflamm Bowel Dis 26(5):662–668. https://doi.org/10.1093/ibd/izz212. (PMID: 10.1093/ibd/izz21231560045)
Abu-Sbeih H, Herrera LN, Tang T, Altan M, Chaftari A-MP, Okhuysen PC, Jenq RR, Wang Y (2019) Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis. J Immunother Cancer 7(1):242. https://doi.org/10.1186/s40425-019-0714-x. (PMID: 10.1186/s40425-019-0714-x314882056729015)
Addiss DG, Shaffer N, Fowler BS, Tauxe RV (1990) The epidemiology of appendicitis and appendectomy in the United States. Am J Epidemiol 132(5):910–925. https://doi.org/10.1093/oxfordjournals.aje.a115734. (PMID: 10.1093/oxfordjournals.aje.a1157342239906)
Becker P, Fichtner-Feigl S, Schilling D (2018) Clinical management of appendicitis. Visc Med 34(6):453–458. https://doi.org/10.1159/000494883. (PMID: 10.1159/000494883306754936341313)
Carr NJ (2000) The pathology of acute appendicitis. Ann Diagn Pathol 4(1):46–58. https://doi.org/10.1016/s1092-9134(00)90011-x. (PMID: 10.1016/s1092-9134(00)90011-x10684382)
Chenfei Zhou JZ (2019) Immunotherapy-based combination strategies for treatment of gastrointestinal cancers: current status and future prospects. Front Med 13(1):12–23. https://doi.org/10.1007/s11684-019-0685-9. (PMID: 10.1007/s11684-019-0685-930796606)
de Wijkerslooth EML, van den Boom AL, Wijnhoven BPL (2019) Variation in classification and postoperative management of complex appendicitis: a European survey. World J Surg 43(2):439–446. https://doi.org/10.1007/s00268-018-4806-4. (PMID: 10.1007/s00268-018-4806-430255334)
Di Saverio S, Podda M, De Simone B, Ceresoli M, Augustin G, Gori A, Boermeester M, Sartelli M, Coccolini F, Tarasconi A, Angelis N, Weber DG, Tolonen M, Birindelli A, Biffl W, Moore EE, Kelly M, Soreide K, Kashuk J et al (2020) Diagnosis and treatment of acute appendicitis: 2020 update of the WSES Jerusalem guidelines. World J Emerg Surg 15(1):27. https://doi.org/10.1186/s13017-020-00306-3. (PMID: 10.1186/s13017-020-00306-3322956447386163)
Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, No D, Gobourne A, Littmann E, Huttenhower C, Pamer EG, Wolchok JD (2016) Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun 7:10391. https://doi.org/10.1038/ncomms10391. (PMID: 10.1038/ncomms10391268370034740747)
Jackson HT, Mongodin EF, Davenport KP, Fraser CM, Sandler AD, Zeichner SL (2014) Culture-independent evaluation of the appendix and rectum microbiomes in children with and without appendicitis. PLoS One 9(4):e95414. https://doi.org/10.1371/journal.pone.0095414. (PMID: 10.1371/journal.pone.0095414247598793997405)
Kim BJ, Jang HJ, Kim HS, Kim JH (2017) Current status of immune checkpoint inhibitors in gastrointestinal cancers [review]. J Cancer 8(8):1460–1465. https://doi.org/10.7150/jca.18470. (PMID: 10.7150/jca.18470286384615479252)
Körner H, Söndenaa K, Söreide JA, Andersen E, Nysted A, Lende TH, Kjellevold KH (1997) Incidence of acute nonperforated and perforated appendicitis: age-specific and sex-specific analysis. World J Surg 21(3):313–317. https://doi.org/10.1007/s002689900235. (PMID: 10.1007/s0026899002359015177)
Lee JH, Park YS, Choi JS (2010) The Epidemiology of appendicitis and appendectomy in south korea: national registry data. J Epidemiol 20(2):97–105. https://doi.org/10.2188/jea.JE20090011. (PMID: 10.2188/jea.JE20090011200233683900807)
Leigh DA, Simmons K, Norman E (1974) Bacterial flora of the appendix fossa in appendicitis and postoperative wound infection. J Clin Pathol 27(12):997–1000. https://doi.org/10.1136/jcp.27.12.997. (PMID: 10.1136/jcp.27.12.9974217805475573)
Mangas C, Leoni-Parvex S, Spataro V (2020) Silent acute appendicitis revealed by PET-CT during treatment with ipilimumab and nivolumab: a new immune-related adverse event. Cancer Immunol Immunother 69(11):2409–2410. https://doi.org/10.1007/s00262-020-02724-3. (PMID: 10.1007/s00262-020-02724-332964272)
Mazuski JE, Tessier JM, May AK, Sawyer RG, Nadler EP, Rosengart MR, Chang PK, O’Neill PJ, Mollen KP, Huston JM, Diaz JJ Jr, Prince JM (2017) the surgical infection society revised guidelines on the management of intra-abdominal infection. Surg Infect (larchmt) 18(1):1–76. https://doi.org/10.1089/sur.2016.261. (PMID: 10.1089/sur.2016.26128085573)
Merlin MA, Shah CN, Shiroff AM (2010) Evidence-based appendicitis: the initial work-up. Postgrad Med 122(3):189–195. https://doi.org/10.3810/pgm.2010.05.2157. (PMID: 10.3810/pgm.2010.05.215720463429)
Omari AH, Khammash MR, Qasaimeh GR, Shammari AK, Yaseen MK, Hammori SK (2014) Acute appendicitis in the elderly: risk factors for perforation. World J Emerg Surg 9(1):6. https://doi.org/10.1186/1749-7922-9-6. (PMID: 10.1186/1749-7922-9-6244289093896723)
Papageorgiou GI, Fergadis E, Skouteris N, Christakos E, Tsakatikas SA, Filippakou A, Papantoni E, Stanc G, Souka E, Valavanis C, Kosmas C (2021) Perforated appendicitis induced by pembrolizumab: a case report and review of the literature. Anticancer Drugs. https://doi.org/10.1097/cad.0000000000001247. (PMID: 10.1097/cad.000000000000124734232951)
Park SH, Park SS, Lee DW, Park HC, Park SC, Hong CW, Sohn DK, Han KS, Chang HJ, Oh JH (2021) Comparison between early surgical treatment and conservative treatment of appendicitis in cancer patients. ANZ J Surg 91(10):2067–2073. https://doi.org/10.1111/ans.17180. (PMID: 10.1111/ans.1718034476891)
Patel C, Purkey SC, Stancher J (2021) S2958 acute appendicitis: a rare complication from nivolumab. Off J Am Coll Gastroenterol 116:S1224–S1225. https://doi.org/10.14309/01.ajg.0000785364.58385.99.
Peeters T, Penders J, Smeekens SP, Galazzo G, Houben B, Netea MG, Savelkoul PH, Gyssens IC (2019) The fecal and mucosal microbiome in acute appendicitis patients: an observational study. Future Microbiol 14:111–127. https://doi.org/10.2217/fmb-2018-0203. (PMID: 10.2217/fmb-2018-020330663346)
Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158–168. https://doi.org/10.1056/NEJMra1703481. (PMID: 10.1056/NEJMra170348129320654)
Rautio M, Saxén H, Siitonen A, Nikku R, Jousimies-Somer H (2000) Bacteriology of histopathologically defined appendicitis in children. Pediatr Infect Dis J 19(11):1078–1083. https://doi.org/10.1097/00006454-200011000-00010. (PMID: 10.1097/00006454-200011000-0001011099090)
Santos D, Chiang YJ, Badgwell B (2016) Appendicitis in cancer patients is often observed and can represent appendiceal malignancy. Am Surg 82(10):1028–1032. (PMID: 10.1177/00031348160820103827779999)
Schülin S, Schlichting N, Blod C, Opitz S, Suttkus A, Stingu CS, Barry K, Lacher M, Bühligen U, Mayer S (2017) The intra- and extraluminal appendiceal microbiome in pediatric patients: a comparative study. Medicine (baltimore) 96(52):e9518. https://doi.org/10.1097/md.0000000000009518. (PMID: 10.1097/md.000000000000951829384958)
Song DW, Park BK, Suh SW, Lee SE, Kim JW, Park J-M, Kim HR, Lee M-K, Choi YS, Kim BG, Park YG (2018) Bacterial culture and antibiotic susceptibility in patients with acute appendicitis. Int J Colorectal Dis 33(4):441–447. https://doi.org/10.1007/s00384-018-2992-z. (PMID: 10.1007/s00384-018-2992-z29488087)
Stewart B, Khanduri P, McCord C, Ohene-Yeboah M, Uranues S, Vega Rivera F, Mock C (2014) Global disease burden of conditions requiring emergency surgery. Br J Surg 101(1):e9-22. https://doi.org/10.1002/bjs.9329. (PMID: 10.1002/bjs.932924272924)
Talan DA, Saltzman DJ, DeUgarte DA, Moran GJ (2019) Methods of conservative antibiotic treatment of acute uncomplicated appendicitis: a systematic review. J Trauma Acute Care Surg 86(4):722–736. https://doi.org/10.1097/ta.0000000000002137. (PMID: 10.1097/ta.000000000000213730516592)
Teng TZJ, Thong XR, Lau KY, Balasubramaniam S, Shelat VG (2021) Acute appendicitis-advances and controversies. World J Gastrointest Surg 13(11):1293–1314. https://doi.org/10.4240/wjgs.v13.i11.1293. (PMID: 10.4240/wjgs.v13.i11.1293349504218649565)
Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB (2020) Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). https://doi.org/10.3390/cancers12030738. (PMID: 10.3390/cancers1203073832245016)
van den Boom AL, de Wijkerslooth EML, Wijnhoven BPL (2020) Systematic review and meta-analysis of postoperative antibiotics for patients with a complex appendicitis. Dig Surg 37(2):101–110. https://doi.org/10.1159/000497482. (PMID: 10.1159/00049748231163433)
van Rossem CC, Schreinemacher MH, Treskes K, van Hogezand RM, van Geloven AA (2014) Duration of antibiotic treatment after appendicectomy for acute complicated appendicitis. Br J Surg 101(6):715–719. https://doi.org/10.1002/bjs.9481. (PMID: 10.1002/bjs.948124668341)
Wang Y, Abu-Sbeih H, Mao E, Ali N, Ali FS, Qiao W, Lum P, Raju G, Shuttlesworth G, Stroehlein J, Diab A (2018a) Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer 6(1):37. https://doi.org/10.1186/s40425-018-0346-6. (PMID: 10.1186/s40425-018-0346-6297476885946546)
Wang Y, Abu-Sbeih H, Mao E, Ali N, Qiao W, Trinh VA, Zobniw C, Johnson DH, Samdani R, Lum P, Shuttlesworth G, Blechacz B, Bresalier R, Miller E, Thirumurthi S, Richards D, Raju G, Stroehlein J, Diab A (2018b) Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm Bowel Dis 24(8):1695–1705. https://doi.org/10.1093/ibd/izy104. (PMID: 10.1093/ibd/izy10429718308)
Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM et al (2018c) Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 24(12):1804–1808. https://doi.org/10.1038/s41591-018-0238-9. (PMID: 10.1038/s41591-018-0238-9304207546322556)
Wang D, Lin J, Yang X, Long J, Bai Y, Yang X, Mao Y, Sang X, Seery S, Zhao H (2019) Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. J Hematol Oncol 12(1):42. https://doi.org/10.1186/s13045-019-0730-9. (PMID: 10.1186/s13045-019-0730-9310143816480748)
Zhong D, Brower-Sinning R, Firek B, Morowitz MJ (2014) Acute appendicitis in children is associated with an abundance of bacteria from the phylum Fusobacteria. J Pediatr Surg 49(3):441–446. https://doi.org/10.1016/j.jpedsurg.2013.06.026. (PMID: 10.1016/j.jpedsurg.2013.06.02624650474)
فهرسة مساهمة: Keywords: Adverse events; Appendicitis; Cancer; Immune checkpoint inhibitor
المشرفين على المادة: 0 (Immune Checkpoint Inhibitors)
0 (Antineoplastic Agents, Immunological)
تواريخ الأحداث: Date Created: 20220927 Date Completed: 20230719 Latest Revision: 20230719
رمز التحديث: 20240628
DOI: 10.1007/s00432-022-04367-6
PMID: 36163559
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-1335
DOI:10.1007/s00432-022-04367-6